Cash from Operations (Quarterly) Chart

View Cash from Operations (Quarterly) for AMGN.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Operations (Quarterly) Chart
Start Trial

Historical Cash from Operations (Quarterly) Data

View and export this data back to 1998. Start Trial.
Date Value
June 30, 2026 4.002B
March 31, 2026 2.189B
December 31, 2025 1.603B
September 30, 2025 4.684B
June 30, 2025 2.28B
March 31, 2025 1.391B
December 31, 2024 4.771B
September 30, 2024 3.571B
June 30, 2024 2.459B
March 31, 2024 689.00M
December 31, 2023 538.00M
September 30, 2023 2.76B
June 30, 2023 4.109B
March 31, 2023 1.064B
December 31, 2022 2.649B
September 30, 2022 2.978B
June 30, 2022 1.93B
March 31, 2022 2.164B
December 31, 2021 2.808B
September 30, 2021 2.418B
June 30, 2021 1.931B
March 31, 2021 2.104B
December 31, 2020 2.153B
September 30, 2020 3.368B
June 30, 2020 2.842B
Date Value
March 31, 2020 2.134B
December 31, 2019 2.514B
September 30, 2019 3.377B
June 30, 2019 1.414B
March 31, 2019 1.845B
December 31, 2018 3.194B
September 30, 2018 3.273B
June 30, 2018 2.102B
March 31, 2018 2.727B
December 31, 2017 3.012B
September 30, 2017 3.454B
June 30, 2017 2.326B
March 31, 2017 2.385B
December 31, 2016 3.10B
September 30, 2016 2.662B
June 30, 2016 2.677B
March 31, 2016 1.915B
December 31, 2015 2.06B
September 30, 2015 2.874B
June 30, 2015 2.814B
March 31, 2015 1.329B
December 31, 2014 2.445B
September 30, 2014 2.741B
June 30, 2014 2.227B
March 31, 2014 1.142B

Cash From Operations Definition

Represents the net cash flow from the company's business operations.

Read full definition.

Cash from Operations (Quarterly) Range, Past 5 Years

View Cash from Operations (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Operations (Quarterly) Benchmarks

View Cash from Operations (Quarterly) Benchmarks
Start Trial
Gilead Sciences, Inc. 3.573B
Regeneron Pharmaceuticals, Inc. 813.00M
AbbVie, Inc. 3.436B
Biogen, Inc. 448.90M
Vertex Pharmaceuticals, Inc. 1.125B